Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

Ulcerative Colitis in Remission Clinical Trial

Official title:
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

Status Completed

Clinical Trial Summary

To demonstrate that import Mesalazine (ASACOL®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (rate of non-emergence of bloody stool), in patients with Ulcerative Colitis in remission, treated for 48 weeks.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01257399
Study type	Interventional
Source	Tillotts Pharma AG
Contact
Status	Completed
Phase	Phase 3
Start date	November 2010
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01301976` - Nutritional State and Intake Nutrients Assessment in Ulcerative Colitis	N/A
Terminated	`NCT03122613` - Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis	N/A
Recruiting	`NCT03501758` - Predicting Relapse of Ulcerative Colitis With Gastrointestinal Ultrasound
Recruiting	`NCT03698812` - A Multicenter Prospective Cohort Study on the Clinical Prognosis of Ulcerative Colitis
Recruiting	`NCT04695964` - Objective Perfusion Rate Assessment by Near-infrared Fluorescence in Ileal Pouch Formation and Ileal-pouch-anal Anastomosis	N/A
Completed	`NCT05656391` - Impact of Bread Diet on Intestinal Dysbiosis and Irritable Bowel Syndrome Symptoms in Quiescent Ulcerative Colitis	N/A